Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease


Por: Ariño, S, Ferrer-Lorente, R, Serrano, G, Zanatto, L, de la Torre, RAMG, Gratacos-Ginès, J, Rubio, AB, Pérez, M, Mateos-Sánchez, C, Aguilar-Bravo, B, Atkinson, S, Xu, ZQ, Cantallops-Vilà, P, Sererols-Viñas, L, Ruiz-Blázquez, P, Rill, A, Fundora, Y, Lozano, JJ, Coll, M, Ochoa, I, Affo, S, Moles, A, Mereu, E, Bataller, R, Pose, E and Sancho-Bru, P

Publicada: 1 ene 2026 Ahead of Print: 1 dic 2025
Resumen:
Background & aims: Animal models poorly recapitulate advanced alcohol-associated liver disease (ALD), precluding the development of new treatments. Organoids have emerged as a powerful human-based preclinical tool; however, current patient-derived liver organoids fail to capture epithelial heterogeneity and require surgical resections, limiting their use in personalized disease modeling. Here, we describe the development of organoids from liver needle biopsies (b-Orgs) obtained from patients with ALD. Methods: b-Orgs were generated from tru-cut biopsies from patients at early (n = 28) and advanced (n = 34) stages of ALD. b-Orgs were characterized by immunofluorescence, bulk and single-cell RNA sequencing, and compared to parental tissues. b-Orgs were used to model ALD progression, identify pathogenic drivers, induce alcohol-associated hepatitis and evaluate response to prednisolone. Results: Phenotypic and functional analysis of b-Orgs showed hepatocyte-enriched features. Single-cell RNA sequencing revealed a heterogeneous cell composition comprising hepatocyte, biliary and progenitor populations, mirroring the epithelial landscape found in patients with advanced ALD. Importantly, b-Orgs preserved disease stage features and revealed an association between ELF3, cell plasticity, and disease progression. Finally, stimulation of b-Orgs with drivers of ALD induced pathophysiological features of alcohol-associated hepatitis, including reactive oxygen species production, lipid accumulation, inflammation and decreased cell proliferation, which were attenuated by prednisolone. Conclusions: We describe a human-based model that captures epithelial complexity and patient-specific features of ALD. This approach enables the identification of drivers of cell plasticity and highlights the potential of organoid-based liver disease modeling for personalized medicine. (c) 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Filiaciones:
Ariño, S:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain

Ferrer-Lorente, R:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

Serrano, G:
 CIMA Univ Navarra, Computat Biol Program, IdiSNA, Pamplona, Spain

Zanatto, L:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

de la Torre, RAMG:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

Gratacos-Ginès, J:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Liver Unit, Barcelona, Spain

Rubio, AB:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Liver Unit, Barcelona, Spain

Pérez, M:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Liver Unit, Barcelona, Spain

Mateos-Sánchez, C:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

Aguilar-Bravo, B:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

Atkinson, S:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Imperial Coll London, Dept Metab Digest & Reprod, London, England

Xu, ZQ:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

Cantallops-Vilà, P:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

Sererols-Viñas, L:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

Ruiz-Blázquez, P:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain

 CSIC, Inst Biomed Res Barcelona, Dept Expt Pathol, Barcelona, Spain

:
 Josep Carreras Leukaemia Res Inst, Barcelona, Spain

Fundora, Y:
 Hosp Clin Barcelona, Dept Gen & Digest Surg, Barcelona, Spain

Lozano, JJ:
 Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain

Coll, M:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Univ Barcelona UB, Barcelona, Spain

Ochoa, I:
 Univ Navarra, Dept Elect Engn TECNUN, San Sebastian, Spain

 Univ Navarra, Data Sci & Artificial Intelligence Inst DATAI, Pamplona, Spain

Affo, S:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

Moles, A:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain

:
 Josep Carreras Leukaemia Res Inst, Barcelona, Spain

Bataller, R:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain

 Hosp Clin Barcelona, Liver Unit, Barcelona, Spain

 Univ Barcelona UB, Barcelona, Spain

Pose, E:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain

 Hosp Clin Barcelona, Liver Unit, Barcelona, Spain

 Univ Barcelona UB, Barcelona, Spain

Sancho-Bru, P:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain

 Univ Barcelona UB, Barcelona, Spain
ISSN: 16000641





Journal of Hepatology
Editorial
Elsevier BV, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Article
Volumen: 84 Número: 1
Páginas: 135-149
WOS Id: 001649602200001
ID de PubMed: 40754225
imagen Bronze

MÉTRICAS